Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 9/20 | 0.39 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | BAZ2B | Q9UIF8 | 2/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL889850 | 0.95 | SIRT1 (0.41) | POLBHRH4SIRT1GAABAZ2B | |
| SCHEMBL12901870 | 0.91 | NOTUM (0.45) | RAB9APOLBNPC1MEN1KMT2A | |
| SCHEMBL889826 | 0.89 | KMT2A (0.40) | RAB9APOLBNPC1MEN1KMT2A | |
| SCHEMBL13183213 | 0.88 | POLB (0.40) | RAB9APOLBNPC1MEN1KMT2A | |
| SCHEMBL889973 | 0.88 | RAB9A (0.43) | RAB9APOLBNPC1MEN1KMT2A | |
| SCHEMBL18165247 | 0.88 | PLG (0.40) | RAB9APOLBNPC1MEN1KMT2A | |
| SCHEMBL887593 | 0.85 | NOTUM (0.49) | BAZ2BNOTUM | |
| SCHEMBL22048825 | 0.84 | RAB9A (0.38) | RAB9APOLBNPC1MEN1KMT2A | |
| SCHEMBL887712 | 0.84 | KDM4E (0.43) | POLBMEN1KMT2ASIRT1GAA | |
| SCHEMBL889800 | 0.83 | RAB9A (0.40) | RAB9APOLBNPC1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210040137-A1 | Oligonucleotide Conjugation Process | ROCHE INNOVATION CENTER COPENHAGEN A/S (CH) | 2021-02-11 | — | — | US | disclosed |
| US-10577388-B2 | Oligonucleotide conjugation process | ROCHE INNOVATION CENTER COPENHAGEN A/S (CH) | 2020-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040137-A1 | Oligonucleotide Conjugation Process | POLN, POLI, DCLRE1B | RAB9A 4007/4885POLB 4/4885NPC1 2247/4885 |
| US-10577388-B2 | Oligonucleotide conjugation process | POLN, POLI, DCLRE1B | RAB9A 4007/4885POLB 4/4885NPC1 2247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.